New cocktail of drugs shows promise for Tough-to-Treat lymphoma
NCT ID NCT02436707
First seen Jan 15, 2026 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial is testing several new combinations of drugs to treat aggressive B-cell lymphoma that has come back or not responded to standard treatment. The study involves 129 participants and compares the new combinations to standard therapy. The main goal is to see if these combinations lead to more tumor shrinkage (complete or partial response) while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
BCCA - Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
Québec, Quebec, G1J 1Z4, Canada
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
What this could lead to
If successful, this could point toward more effective treatment options for patients with aggressive B-cell lymphoma that has returned or not responded to prior therapy.
What could go wrong
This is an early-phase (phase 2) trial with a small number of participants (129). The new combinations may not prove more effective than standard treatment and could have significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.